Frontlight ResearchEarly access
WithdrawnNo phase
Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Starts
- Jul 2027
- Expected to end
- Jan 2030
- Type of study
- Interventional
- Treatments tested
- Parathyroid Allotransplant
- Record updated
- 21 August 2026
- Why it stopped
- Regulatory challenges
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Individual diagnosed with hypocalcemia secondary to; Hypoparathyroidism:; Prior anterior cervical neck surgery resulting in hypoparathyroidism; Congenital absence or malformation of parathyroid glands during development; Presence of hypoparathyroidism for at least one year; Failure of medical treatment for hypocalcemia, including need for IV calcium, with negative impact on quality of life and daily function; Age 18-80 years; Lives in the greater Birmingham region for the duration of the trial; Fluent in the English Language; Willing to comply with screening, protocol and all required procedures
Who cannot take part
- Current smoker (smoking cessation must have occurred 3 months prior to enrollment)
- Resources deemed inadequate to support necessary post-transplant care
- Any active malignancy, except non-melanoma skin cancer
- History of significant psychiatric illness
- Allergy, hypersensitivity, or intolerance of expected immunosuppressive agents (i.e. Thymoglobulin®, tacrolimus, etc.)
- Documented history of gross non-adherence to medical therapies
- Significant functional/cognitive impairment without reliable caregiver
- Presence of active documented systemic infection or recent systemic infection within the past 3 months
- Seropositivity for HIV, HBV core antibody or antigen, HCV, HTLV-1
- Psychosocial problems (including alcoholism, drug abuse, documented behavioral disorders)
- History of ischemic cardiomyopathy with ejection fraction <20%, uncontrolled diabetes mellitus (Hgb A1c >10), thrombophilia or other clotting or bleeding disorders, significant heart, liver, kidney or central nervous system disease
- Dependence on nursing home or other long-term care provider
- Severe osteoporosis
- Chemical and/or alcohol dependency or abuse
Where in United States
- University of Alabama at BirminghamBirmingham, United States
About the trial
What the trial wants to find out
Options for treatment of severe, refractory hypocalcemia are limited for the thousands of patients in the United States who suffer from hypoparathyroidism. Parathyroid allotransplantation is an emerging treatment that provides hope for these individuals. Currently, this therapy has only been successfully provided by a few centers in the world. In the UAB PATH trial, we propose to become one of the few centers worldwide to successfully achieve parathyroid allotransplantation in transplant-naïve patients.
Treatments tested
- Parathyroid Allotransplant
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 21 August 2026